Recent Updates
Recently added Catalysts
VNDA

Vanda Pharmaceuticals Announces Participation at Evercore ISI

Thursday, October 14, 2021 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: WASHINGTON, Oct. 14, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it will participate at Evercore ISI's Catalyst Day on Monday, October 18, 2021. Mihael H. Polymeropoulos, M.D., Vanda's President, CEO and Chairman of the Board, will
Price reaction · baseline $18.16 (2021-10-13 close) · hit after-hours · clean, no other VNDA news in the window
day 0 close
+1%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+121%
120-day peak, hindsight
Typical move
19.9%
average across 7 past catalysts
Cash runway
~16 mo
Low dilution risk
Lead asset
Imsidolimab
Phase 2 · Palmoplantar Pustulosis

Full Press Release Details

WASHINGTON, Oct. 14, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it will participate at Evercore ISI's Catalyst Day on Monday, October 18, 2021. Mihael H. Polymeropoulos, M.D., Vanda's President, CEO and Chairman of the Board, will take part in a virtual fireside chat at 1:30 PM ET.
About Vanda Pharmaceuticals Inc.
Chief Corporate Affairs and Communications Officer
Vanda Pharmaceuticals Inc.
Head of Corporate Affairs
Vanda Pharmaceuticals Inc.
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
ShareAdd on Google
Tags: VNDA Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Oct 14, 2021

Biotech snapshot

Cash runway
$170M liquidity · $10M/mo burn
~16 mo
Low dilution risk
Lead asset
ImsidolimabPhase 2
Palmoplantar Pustulosis →

Catalyst track record

+121%
best trade around VNDA's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for VNDA.

See every catalyst's timing & PoA →